Aug 6, 2026 08:00AM
May 13, 2026 04:01PM
Mar 10, 2026 04:01PM
Feb 2, 2026 08:01AM
Feb 2, 2026 08:00AM
Dec 18, 2025 04:05PM
Dec 18, 2025 04:05PM vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
Nov 6, 2025 04:15PM
Oct 9, 2025 08:00AM
Oct 9, 2025 08:00AM
Sep 15, 2025 08:00AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 12, 2025 04:15PM vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 7, 2025 08:00AM
Aug 7, 2025 08:00AM
May 19, 2025 09:00AM
May 19, 2025 09:00AM
May 15, 2025 04:01PM
May 15, 2025 12:00PM
May 15, 2025 12:00PM vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
Mar 20, 2025 05:35PM
Mar 17, 2025 08:30AM
Mar 17, 2025 08:30AM
Dec 2, 2024 04:05PM
Nov 12, 2024 04:05PM
Aug 8, 2024 04:15PM
Jul 26, 2024 04:05PM vTv Therapeutics (VTVT) Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
Jul 26, 2024 04:05PM
Jun 24, 2024 04:08PM
Jun 24, 2024 04:05PM
May 9, 2024 04:51PM
Mar 13, 2024 08:00AM
Mar 4, 2024 08:00AM
Mar 4, 2024 08:00AM vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
Mar 1, 2024 08:00AM
Feb 28, 2024 08:01AM
Feb 28, 2024 08:00AM
Nov 9, 2023 04:30PM
Nov 8, 2023 08:00AM
Nov 2, 2023 08:05AM
Nov 2, 2023 08:00AM vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
Nov 1, 2023 08:01AM
Nov 1, 2023 08:00AM
Aug 11, 2023 04:31PM
Aug 11, 2023 04:30PM
Jun 16, 2023 08:03AM
Jun 16, 2023 08:00AM
May 24, 2023 09:03AM vTv Therapeutics (VTVT) Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
May 24, 2023 09:00AM

1,180,379 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All